Cancer Therapy News and Research

RSS

microRNA shown to reduce lung cancer growth

A small RNA molecule, known as let-7 microRNA (miRNA), substantially reduced cancer growth in multiple mouse models of lung cancer, according to work by researchers at Yale University and Asuragen, Inc., published in the journal Cell Cycle.

24 Mar 2008

Review of supplement use among US cancer patients

Many of the 10 million cancer patients in the US are taking nutritional supplements, but an accurate assessment of the frequency is not well appreciated.

24 Mar 2008

Equality in breast cancer care study

It has been said that cancer doesn't discriminate. Sadly, that is not always the case when it comes to cancer care.

24 Mar 2008

Review of supplement use among US cancer patients

Many of the 10 million cancer patients in the US are taking nutritional supplements, but an accurate assessment of the frequency is not well appreciated.

20 Mar 2008

Shorter radiotherapy courses can benefit breast cancer patients

A LOWER total dose of radiotherapy, delivered in fewer, larger treatments has been shown to be as effective as the international standard of a higher total dose delivered over a longer time to treat women with early breast cancer according to new research published in the Lancetand Lancet Oncology.

20 Mar 2008

Prostate size and other neglected factors influence prostate cancer treatment satisfaction

Men with prostate cancer and their partners face difficult decisions regarding treatment, and accurate information regarding expected outcomes can be hard to find, according to results of a multi-center study published Wednesday in the New England Journal of Medicine.

20 Mar 2008

Zebrafish enables cell regeneration studies to help understand, treat human disease

One aquarium fish's uncanny ability to regenerate essentially any cell type has given scientists a way to mimic cell loss that occurs in diseases such as Parkinson's and diabetes then watch how the fish make more of them.

18 Mar 2008

Study examines changes in quality of life after head and neck cancer treatment

In the year following their first treatment, patients with head and neck cancer report declines in their physical quality of life but improvements in their mental health quality of life, according to a report in the March issue of Archives of Otolaryngology-Head & Neck Surgery.

18 Mar 2008

New technique detects early stages of colon cancer without a biopsy

Doctors may one day be able to detect early stages of colon cancer without a biopsy, using a new technique developed by researchers at the Stanford University School of Medicine.

18 Mar 2008

Study explains fundamental process of tumor growth

Nearly 80 years ago, scientist Otto Warburg observed that cancer cells perform energy metabolism in a way that is different from normal adult cells.

14 Mar 2008

Study helps explain how tumor cells rapidly grow and proliferate

Nearly 80 years ago, scientist Otto Warburg observed that cancer cells perform energy metabolism in a way that is different from normal adult cells.

13 Mar 2008

Researchers find cause of severe allergic reaction to cetuximab

Clinicians have been perplexed by the fact that some patients given the drug cetuximab - an immune-based therapy commonly used to treat persons diagnosed with head and neck cancer, or colon cancer - have a severe and rapid adverse reaction to the drug.

13 Mar 2008

AstraZeneca completes enrollment in phase III studies of cancer drug vandetanib

AstraZeneca has announced that it has completed patient enrollment in two pivotal Phase III studies for vandetanib, the company's investigational, once-daily oral anti-cancer drug, for the second-line treatment of non-small cell lung cancer (NSCLC).

13 Mar 2008

New cancer research model bridges health disparity gap

The Accelerated Community Oncology Research Network (ACORN), a national oncology clinical trial network, has announced that it is bridging the disparity gap in healthcare to underserved communities by enrolling more than double the national average of African Americans in cancer-related clinical trials.

12 Mar 2008

Femara helps protect against return of breast cancer after completing Tamoxifen therapy

Women may reduce the risk of their breast cancer returning by starting treatment with Femara (letrozole tablets) anywhere from one to seven years after finishing tamoxifen therapy, according to a new analysis published in the Journal of Clinical Oncology.

11 Mar 2008

Cardiac effects associated with breast cancer treatment appear lower with dose-dense chemotherapy

A new pilot study by investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) found that breast cancer patients can be treated safely with a "dose-dense" regimen of standard chemotherapy agents and the antibody trastuzumab (Herceptin), a drug that has previously been shown to cause cardiac toxicity.

11 Mar 2008

Cardiac effects associated with breast cancer treatment appear lower

A new pilot study by investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) found that breast cancer patients can be treated safely with a “dose-dense” regimen of standard chemotherapy agents and the antibody trastuzumab (Herceptin®), a drug that has previously been shown to cause cardiac toxicity.

10 Mar 2008

Curing cancer with natural products - a case for shamans and herb women?

Not at all, for many chemotherapies to fight cancer applied in modern medicine are natural products or were developed on the basis of natural substances. Thus, taxanes used in prostate and breast cancer treatment are made from yew trees. The popular periwinkle plant, which grows along the ground of many front yards, is the source of vinca alkaloids that are effective, for example, against malignant lymphomas. The modern anti-cancer drugs topotecan and irinotecan are derived from a constituent of the Chinese Happy Tree.

6 Mar 2008

Genetic mutations involved in IGF-I signaling pathway influence life span

Mutations in genes governing an important cell-signaling pathway influence human longevity, scientists at the Albert Einstein College of Medicine of Yeshiva University have found.

6 Mar 2008

Bioniche receives fast track for bladder cancer therapy

Bioniche Life Sciences Inc. has announced that it has received notice from the U.S. Food and Drug Administration (FDA) that its therapy for first-line non-muscle-invasive bladder cancer meets the criteria for Fast Track designation.

6 Mar 2008